Compare Costco Wholesale Corporation (COST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Costco Wholesale Corporation trades at $922.75 (market cap $408.78B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Costco Wholesale Corporation is far larger — about 229.7× Recursion Pharmaceuticals Inc's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| COST | RXRX | |
|---|---|---|
Market Cap | $408.78B | $1.78B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $6.79 |
52-Week Low | $849.63 | $2.84 |
Enterprise Value | $396.92B | $1.19B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $921.73, down 0.51% on the day, with a bearish technical signal but strong fundamental growth. Revenue reached $275.24B in 2025 with net income of $8.10B, and March 2026 sales grew 11.3% year-over-year. The stock carries premium valuations (P/E 46.37, P/S 1.4) while maintaining steady margin expansion. Analyst consensus remains strongly bullish with a $1,120 price target, though recent earnings miss in Q1 2026 highlights execution risks amid high expectations.
Outlook: Costco's membership fee increase and warehouse expansion support long-term growth, but elevated valuation requires flawless execution. Risks include competitive pressures and macroeconomic sensitivity. Institutional accumulation continues, with 65% analyst buy ratings signaling confidence in the company's resilient business model and cash flow generation.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
